ANI Pharmaceuticals (NASDAQ: ANIP) executive sells shares, withholds stock for taxes

Rhea-AI Filing Summary

ANI Pharmaceuticals executive Christopher Mutz reported recent stock transactions in ANI PHARMACEUTICALS INC common shares. He sold 2,121 shares on March 6, 2026 at $74.22 per share and 3,602 shares on March 9, 2026 at $74.18 per share, both as open‑market sales under a Rule 10b5‑1 trading plan adopted on June 16, 2025. Separately, 3,314 shares were withheld on March 7, 2026 at $74.04 per share to cover tax obligations tied to the vesting of 6,476 restricted shares. After these transactions, he directly holds 94,471 shares of ANI common stock.

Insights

Equity compensation and insider-trading specialist

Routine 10b5‑1 sales and tax withholding with sizable stake retained.

Head of Rare Disease Christopher Mutz sold a total of 5,723 shares of ANI PHARMACEUTICALS common stock in two open‑market transactions around $74 per share. A further 3,314 shares were disposed of to satisfy taxes on vesting restricted stock.

The filing notes these sales were made under a pre‑arranged Rule 10b5‑1 trading plan adopted on June 16, 2025, which indicates they were scheduled in advance rather than timed discretionarily. No derivative exercises are reported, and no remaining option positions are shown.

After these moves, Mutz directly holds 94,471 shares, suggesting the net share reduction is modest relative to his remaining position. The transactions appear to be routine liquidity and tax‑management events rather than a major change in equity exposure.

Insider Trade Summary 10b5-1

Net Seller: 5,723 shares ($424,617)

Net Sell 3 txns

Insider Mutz Christopher

Role HEAD OF RARE DISEASE

Sold 5,723 shs ($425K)

Type	Security	Shares	Price	Value
Sale	Common Stock	3,602	$74.18	$267K
Tax Withholding	Common Stock	3,314	$74.04	$245K
Sale	Common Stock	2,121	$74.22	$157K

Holdings After Transaction: Common Stock — 94,471 shares (Direct)

Footnotes (1)

1. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 16, 2025. The shares were sold in multiple trades at prices ranging from $73.14 to $75.00. The price reported above reflects the weighted average sales price. Shares withheld for tax purposes exempt under Rule 16(b)-3 in connection with the vesting of 6,476 shares of restricted stock, the grant of which was previously reported. The shares were sold in multiple trades at prices ranging from $73.27 to $74.81. The price reported above reflects the weighted average sales price.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Mutz Christopher

(Last) (First) (Middle)

C/O ANI PHARMACEUTICALS, INC.

210 MAIN STREET WEST

(Street)

BAUDETTE MN 56623

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
ANI PHARMACEUTICALS INC [ ANIP ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	HEAD OF RARE DISEASE

3. Date of Earliest Transaction (Month/Day/Year)
03/06/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/06/2026		S(1)		2,121	D	$74.22(2)	101,387	D
Common Stock	03/07/2026		F(3)		3,314	D	$74.04	98,073	D
Common Stock	03/09/2026		S(1)		3,602	D	$74.18(4)	94,471	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 16, 2025.

2. The shares were sold in multiple trades at prices ranging from $73.14 to $75.00. The price reported above reflects the weighted average sales price.

3. Shares withheld for tax purposes exempt under Rule 16(b)-3 in connection with the vesting of 6,476 shares of restricted stock, the grant of which was previously reported.

4. The shares were sold in multiple trades at prices ranging from $73.27 to $74.81. The price reported above reflects the weighted average sales price.

Remarks:

	/s/ Christopher Mutz, by attorney-in-fact Meredith W. Cook	03/10/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.